http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668089-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_988a6f37a695a0b266041aa15a184fd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5c70b398c52bd7f3e6fa148bfa31989 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593 |
| filingDate | 2018-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6880d38a0b4ff55f6a02c92b5744b21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdb357196c409ed5bd3ad62b250c5831 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3e863de5936353d468641d43e0ac4bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b303da780eb127d0cb6435e2d0f75e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e2f681ae8f0734bcf7adf9f786630d6 |
| publicationDate | 2020-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10668089-B2 |
| titleOfInvention | Method of treating and preventing secondary hyperparathyroidism |
| abstract | The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance. |
| priorityDate | 2006-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 719.